BRISTOL MYERS SQUIBB’S BREYANZI APPROVED BY THE U.S. FDA AS THE FIRST AND ONLY CAR T CELL THERAPY FOR ADULTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)

Reuters · 19h ago

Please log in to view news